Puma BioTech | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 54.5 M

Revenue: As of FY2025 Q3, the actual value is USD 54.5 M, beating the estimate of USD 51 M.

EPS: As of FY2025 Q3, the actual value is USD 0.17, beating the estimate of USD 0.045.

EBIT: As of FY2025 Q3, the actual value is USD 10.1 M.

Segment Revenue

• Product Revenue, Net: $51.9 million for Q3 2025, compared to $56.1 million for Q3 2024. For the first nine months of 2025, product revenue was $144.2 million, compared to $140.8 million for the same period in 2024.
• Royalty Revenue: $2.6 million for Q3 2025, compared to $24.4 million for Q3 2024. For the first nine months of 2025, royalty revenue was $8.7 million, compared to $30.6 million for the same period in 2024.

Operational Metrics

• Net Income: $8.8 million for Q3 2025, compared to $20.3 million for Q3 2024. For the first nine months of 2025, net income was $17.7 million, compared to $11.0 million for the same period in 2024.
• Non-GAAP Adjusted Net Income: $10.5 million for Q3 2025, compared to $22.4 million for Q3 2024. For the first nine months of 2025, non-GAAP adjusted net income was $23.0 million, compared to $17.5 million for the same period in 2024.
• Operating Costs and Expenses: $44.9 million for Q3 2025, compared to $58.4 million for Q3 2024. For the first nine months of 2025, operating costs were $132.7 million, compared to $153.8 million for the same period in 2024.

Cash Flow

• Net Cash Provided by Operating Activities: $9.7 million for Q3 2025, compared to $11.0 million for Q3 2024. For the first nine months of 2025, net cash provided by operating activities was $27.4 million, compared to $23.3 million for the same period in 2024.

Unique Metrics

• Cost of Sales: $12.2 million for Q3 2025, compared to $29.1 million for Q3 2024. For the first nine months of 2025, cost of sales was $35.0 million, compared to $50.5 million for the same period in 2024.
• Research and Development Expenses: $15.9 million for Q3 2025, compared to $12.5 million for Q3 2024. For the first nine months of 2025, R&D expenses were $45.2 million, compared to $39.8 million for the same period in 2024.

Outlook / Guidance

• Fourth Quarter and Full Year 2025 Financial Outlook: Net product revenue is expected to be $54–$56 million for Q4 2025 and $198–$200 million for the full year 2025. Royalty revenue is projected to be $13–$14 million for Q4 2025 and $22–$23 million for the full year 2025. Total revenue is anticipated to be $67–$70 million for Q4 2025 and $220–$223 million for the full year 2025.